Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 1Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 302Carboplatin 228Cisplatin 157Gemcitabine 155Paclitaxel 154Pemetrexed 122Bevacizumab 121Docetaxel 105Oxaliplatin 84durvalumab 82Nivolumab 81Fluorouracil 81Dexamethasone 79Cyclophosphamide 78atezolizumab 77130-nm albumin-bound paclitaxel 73Fulvestrant 71Capecitabine 69Injections 65Leucovorin 64Cetuximab 63Rituximab 56Lenalidomide 52fludarabine 51venetoclax 46Prednisone 45Irinotecan 44enzalutamide 41Letrozole 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × penpulimab × 90 days × Clear all
NCT05563480 2026-04-07

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
47 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06821503 2026-03-10

Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
72 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡